The role of gastroesophageal reflux and other factors during progression to esophageal adenocarcinoma

Cancer Epidemiology Biomarkers and Prevention

Volumn 24, Issue 7, 2015, Pages 1012-1023

  Hazelton, William D ^a   Curtius, Kit ^b   Inadomi, John M ^b   L vaughan, Thomas ^a,c   Meza, Rafael ^d   Rubenstein, Joel H ^e,f   Hur, Chin ^g,h   Luebeck, E Georg ^a  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MICHIGAN SCHOOL OF PUBLIC HEALTH   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^f VETERANS AFFAIRS MEDICAL CENTER   (United States)

^g MASSACHUSETTS GENERAL HOSPITAL   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON PUMP INHIBITOR;

ADULT; AGED; ARTICLE; BODY MASS; CANCER INCIDENCE; CANCER RISK; CARCINOGENESIS; CONTROLLED STUDY; DISEASE COURSE; DRUG USE; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CARCINOGENESIS; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; MAJOR CLINICAL STUDY; MALE; MAXIMUM LIKELIHOOD METHOD; MIDDLE AGED; MODEL; MONTE CARLO METHOD; MULTISCALE MODEL; OBESITY; PRIORITY JOURNAL; PROBABILITY; SMOKING; VERY ELDERLY; ADENOCARCINOMA; CANCER REGISTRY; COMPLICATION; ESOPHAGEAL NEOPLASMS; FOLLOW UP; INCIDENCE; PREVALENCE; PROCEDURES; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TIME FACTOR; UNITED STATES; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GASTROESOPHAGEAL REFLUX; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PREVALENCE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SEER PROGRAM; TIME FACTORS; UNITED STATES; YOUNG ADULT;

EID: 84941758218     PISSN: 10559965     EISSN: 15387755     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-15-0323-T     Document Type: Article

References (60)

1. Cook MB, Chow WH, Devesa SS. Oesophageal cancer incidence in the United States by race, sex, and histologic type, 1977-2005. Br J Cancer 2009;101:855-9.
2. Hur C, Miller M, Kong CY, Dowling EC, Nattinger KJ, Dunn M, et al. Trends in esophageal adenocarcinoma incidence and mortality. Cancer 2013;119:1149-58.
3. Vizcaino AP, Moreno V, Lambert R, Parkin DM. Time trends incidence of both major histological types of oesophageal carcinomas in selected countries 1973-1995 (vol 99, pg 860, 2002). Int J Cancer 2002;101: 599.
4. Rutegard M, Nordenstedt H, Lu Y, Lagergren J, Lagergren P. Sex-specific exposure prevalence of established risk factors for oesophageal adenocarcinoma. Br J Cancer 2010;103:735-40.
5. Kubo A, Cook MB, Shaheen NJ, Vaughan TL, Whiteman DC, Murray L, et al. Sex-specific associations between body mass index, waist circumference and the risk of Barrett's oesophagus: A pooled analysis from the international BEACON consortium. Gut 2013;62:1684-91.
6. Hoyo C, Cook MB, Kamangar F, Freedman ND, Whiteman DC, Bernstein L, et al. Body mass index in relation to oesophageal and oesophagogastric junction adenocarcinomas: A pooled analysis from the International BEACON Consortium. Int J Epidemiol 2012;41:1706-18.
7. O'Doherty MG, Freedman ND, Hollenbeck AR, Schatzkin A, Abnet CC. A prospective cohort study of obesity and risk of oesophageal and gastric adenocarcinoma in the NIH-AARP Diet and Health Study. Gut 2012;61: 1261-8.
8. Anderson LA, Murphy SJ, Johnston BT, Watson RG, Ferguson HR, Bamford KB, et al. Relationship between Helicobacter pylori infection and gastric atrophy and the stages of the oesophageal inflammation, metaplasia, adenocarcinoma sequence: results from the FINBAR case-control study. Gut 2008;57:734-9.
9. Shaheen NJ. What is behind the remarkable increase in esophageal adenocarcinoma? Am J Gastroenterol 2014;109:345-7.
10. Rubenstein JH, Taylor JB. Meta-analysis: The association of oesophageal adenocarcinoma with symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther 2010;32:1222-7.
11. Falk GW, Jacobson BC, Riddell RH, Rubenstein JH, El-Zimaity H, Drewes AM, et al. Barrett's esophagus: prevalence-incidence and etiology-origins. Ann Ny Acad Sci 2011;1232:1-17.
12. Xian W, Ho KY, Crum CP, McKeon F. Cellular origin of Barrett's esophagus: controversy and therapeutic implications. Gastroenterology 2012;142: 1424-30.
13. Reid BJ, Levine DS, Longton G, Blount PL, Rabinovitch PS. Predictors of progression to cancer in Barrett's esophagus: baseline histology and flow cytometry identify low- And high-risk patient subsets. Am J Gastroenterol 2000;95:1669-76.
14. Fan X, Snyder N. Prevalence of Barrett's esophagus in patients with or without GERD symptoms: role of race, age, and gender. Dig Dis Sci 2009; 54:572-7.
15. El-Serag HB, Tran T, Richardson P, Ergun G. Anthropometric correlates of intragastric pressure. Scand J Gastroenterol 2006;41:887-91.
16. Anand G, Katz PO. Gastroesophageal reflux disease and obesity. Gastroenterol Clin North Am 2010;39:39.
17. Emerenziani S, Rescio MP, Guarino MPL, Cicala M. Gastro-esophageal reflux disease and obesity, where is the link? World J Gastroenterol 2013;19:6536-9.
18. Boeckxstaens GE. Review article: The pathophysiology of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2007;26:149-60.
19. Edelstein ZR, Bronner MP, Rosen SN, Vaughan TL. Risk factors for Barrett's esophagus among patients with gastroesophageal reflux disease: A community clinic-based case-control study. Am J Gastroenterol 2009;104: 834-42.
20. Tselepis C, Perry I, Jankowski J. Barrett's esophagus: disregulation of cell cycling and intercellular adhesion in the metaplasia-dysplasia-carcinoma sequence. Digestion 2000;61:1-5.
21. Reid BJ, Prevo LJ, Galipeau PC, Sanchez CA, Longton G, Levine DS, et al. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Am J Gastroenterol 2001;96:2839-48.
22. Maley CC, Galipeau PC, Li X, Sanchez CA, Paulson TG, Reid BJ. Selectively advantageous mutations and hitchhikers in neoplasms: p16 lesions are selected in Barrett's esophagus. Cancer Res 2004;64:3414-27.
23. Alvarez H, Opalinska J, Zhou L, Sohal D, Fazzari MJ, Yu Y, et al. Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis. PLoS Genet 2011;7: E1001356.
24. Wu IC, Zhao Y, Zhai R, Liu CY, Chen F, Ter-Minassian M, et al. Interactions between genetic polymorphisms in the apoptotic pathway and environmental factors on esophageal adenocarcinoma risk. Carcinogenesis 2011; 32:502-6.
25. Zhai RH, Chen F, Liu G, Su L, Kulke MH, Asomaning K, et al. Interactions among genetic variants in apoptosis pathway genes, reflux symptoms, body mass index, and smoking indicate two distinct etiologic patterns of esophageal adenocarcinoma. J Clin Oncol 2010;28:2445-51.
26. Zhai RH, Liu G, Asomaning K, Su L, Kulke MH, Heist RS, et al. Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk. Carcinogenesis 2008;29:2330-4.
27. SEER. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER-Stat Database: Incidence - SEER 9 Regs Research Data, Nov 2011 Sub (1973-2010) -Linked To County Attributes-Total U.S., 1969-2010 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2013, based on the November 2012 submission.
28. Levine DM, Ek WE, Zhang R, Liu X, Onstad L, Sather C, et al. Agenome-wide association study identifies new susceptibility loci for esophageal adenocarcinoma and Barrett's esophagus. Nat Genet 2013;45:1487-93.
29. Ek WE, Levine DM, D'Amato M, Pedersen NL, Magnusson PK, Bresso F, et al. Germline genetic contributions to risk for esophageal adenocarcinoma, Barrett's esophagus, and gastroesophageal reflux. J Natl Cancer Inst 2013;105:1711-8.
30. Talley NJ, Zinsmeister AR, Schleck CD, Melton LJ. Dyspepsia and dyspepsia subgroups-a population-based study. Gastroenterology 1992;102: 1259-68.
31. Locke GR III, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ III. Prevalence and clinical spectrum of gastroesophageal reflux: A population-based study in Olmsted County, Minnesota. Gastroenterology 1997;112: 1448-56.
32. Locke GR III, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ III. Risk factors associated with symptoms of gastroesophageal reflux.AmJ Med 1999;106: 642-9.
33. Ruigomez A, Rodriguez LAG, Wallander MA, Johansson S, Graffner H, Dent J. Natural history of gastro-oesophageal reflux disease diagnosed in general practice. Aliment Pharm Ther 2004;20:751-60.
34. Ruigomez A, Wallander MA, Lundborg P, Johansson S, Rodriguez LAG. Gastroesophageal reflux disease in children and adolescents in primary care. Scand J Gastroenterol 2010;45:139-46.
35. Dent J, El-Serag HB, Wallander MA, Johansson S. Epidemiology of gastro-oesophageal reflux disease: A systematic review. Gut 2005;54: 710-7.
36. Flegal KM, Carroll MD, Kuczmarski RJ, Johnson CL. Overweight and obesity in the United States: prevalence and trends, 1960-1994. Int J Obes Relat Metab Disord 1998;22:39-47.
37. Flegal KM, Carroll MD, Kit BK, Ogden CL. Prevalence of obesity and trends in the distribution of body mass index among US adults, 1999-2010. JAMA 2012;307:491-7.
38. Komlos J, Brabec M. The trend of BMI values of U.S. adults by deciles, birth cohorts 1882-1986 stratified by gender and ethnicity. Econ Hum Biol 2011;9:234-50.
39. Grad YH, Lipsitch M, Aiello AE. Secular trends in Helicobacter pylori seroprevalence in adults in the United States: Evidence for sustained race/ethnic disparities. Am J Epidemiol 2012;175:54-9.
40. Banatvala N, Mayo K, Megraud F, Jennings R, Deeks JJ, Feldman RA. The cohort effect and Helicobacter pylori. J Infect Dis 1993;168:219-21.
41. Thrift AP, Kramer JR, Qureshi Z, Richardson PA, El-Serag HB. Age at onset of GERD symptoms predicts risk of Barrett's esophagus. Am J Gastroenterol 2013;108:915-22.
42. Taylor JB, Rubenstein JH. Meta-analyses of the effect of symptoms of gastroesophageal reflux on the risk of Barrett's esophagus. Am J Gastroenterol 2010;105:1729.
43. Bonde P, Sui G, Dhara S, Wang J, Broor A, Kim IF, et al. Cytogenetic characterization and gene expression profiling in the rat refluxinduced esophageal tumor model. J Thorac Ardiovasc Surg 2007;133: 763-9.
44. Wang DH, Clemons NJ, Miyashita T, Dupuy AJ, Zhang W, Szczepny A, et al. Aberrant epithelial-mesenchymal Hedgehog signaling characterizes Barrett's metaplasia. Gastroenterology 2010;138:1810-22.
45. Triadafilopoulos G. Proton pump inhibitors for Barrett's oesophagus. Gut 2000;46:144-6.
46. Hvid-Jensen F, Pedersen L, Funch-Jensen P, Drewes AM. Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: A nationwide study of 9883 patients. Aliment Pharm Ther 2014;39:984-91.
47. Sital RR, Kusters JG, De Rooij FW, Kuipers EJ, Siersema PD. Bile acids and Barrett's oesophagus: A sine qua non or coincidence? Scand J Gastroenterol Suppl 2006;243:11-7.
48. Yang L, Chaudhary N, Baghdadi J, Pei Z. Microbiome in reflux disorders and esophageal adenocarcinoma. Cancer J 2014;20:207-10.
49. Luebeck EG, Curtius K, Jeon J, Hazelton WD. Impact of tumor progression on cancer incidence curves. Cancer Res 2013;73:1086-96.
50. Kong CY, Kroep S, Curtius K, Hazelton WD, Jeon J, Meza R, et al. Exploring the recent trend in esophageal adenocarcinoma incidence and mortality using comparative simulation modeling. Cancer Epidemiol Biomarkers Prev 2014;23:997-1006.
51. Arias E. United States life tables, 2000. Natl Vital Stat Rep 2002;51:1-38.
52. Holford TR, Levy DT, McKay LA, Clarke L, Racine B, Meza R, et al. Patterns of birth cohort-specific smoking histories, 1965-2009. Am J Prev Med 2014;46:e31-7.
53. Anderson C, Burns DM, Dodd KW, Feuer EJ. Chapter 2: birth-cohortspecific estimates of smoking behaviors for the U.S. population. Risk Analysis 2012;32(Suppl. 1):S14-S24.
54. Proton pump inhibitors BPCA drug use review and duration of use analysis, OSE RCM #: 2010-306. 10903 New Hampshire Avenue, Silver Spring, MD 20993: Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Surveillance and Epidemiology; April 30, 2010. p. 1-28.
55. Rotman SR, Bishop TF. Proton pump inhibitor use in the U.S. ambulatory setting, 2002-2009. PloS ONE 2013;8:e56060.
56. Nicholson A, Jankowski J. Acid reflux and oesophageal cancer. Recent Results Cancer Res 2011;185:65-82.
57. Whiteman DC, Sadeghi S, Pandeya N, Smithers BM, Gotley DC, Bain CJ, et al. Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut 2008;57:173-80.
58. Rubenstein JH, Morgenstern H, Appelman H, Scheiman J, Schoenfeld P, McMahon LF Jr, et al. Prediction of Barrett's esophagus among men. Am J Gastroenterol 2013;108:353-62.
59. Lubin JH, Cook MB, Pandeya N, Vaughan TL, Abnet CC, Giffen C, et al. The importance of exposure rate on odds ratios by cigarette smoking and alcohol consumption for esophageal adenocarcinoma and squamous cell carcinoma in the Barrett's Esophagus and Esophageal Adenocarcinoma Consortium. Cancer Epidemiol 2012;36: 306-16.
60. Reid BJ, Li X, Galipeau PC, Vaughan TL. Barrett's oesophagus and oesophageal adenocarcinoma: Time for a new synthesis. Nat Rev Cancer 2010; 10:87-101.